Tri Stage Venous Cannulae
Sorin Group Italia S.R.L. · Decision date Sep 28, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on 2026-09-28 for K262052, Tri Stage Venous Cannulae, submitted by Sorin Group Italia S.R.L. of Mirandola, Italy. The device falls under regulation 870.4210, product code DWF, device class 2, in the cardiovascular specialty, with the classification name Catheter, Cannula And Tubing, Vascular, Cardiopulmonary Bypass. The application was received 06/18/2026 and is listed as a traditional 510(k), not reviewed by a third party, not a combination product, and without an authorized predetermined change control plan.
SESE indicates 510(k) clearance rather than PMA approval. The TPLC listing places K262052 among Sorin Group Italia's premarket reviews for this regulation, alongside entries such as K253671 Dual Stage Venous Cannulae and K263092 Dual Stage Venous Cannulae. The source does not include a summary statement, so the specific design features distinguishing the tri stage configuration, its indications, and any performance data remain unknown from these records.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 28, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K262052
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Sorin Group Italia S.R.L.
- Product code
- DWF
- Decision code
- SESE
- Decision date
- Sep 28, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Catheter, Cannula And Tubing, Vascular, Cardiopulmonary Bypass.
- Applicant
- Sorin Group Italia S.R.L.
- Product code
- DWF
- FDA device class
- 2
FDA decision timeline
K262052 received
Application receipt date recorded by FDA.
K262052 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code DWF
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
AngioVac F1885K263076 | AngioDynamics, Inc. | 510(k) clearance | Oct 30, 2026 | FDA |
DLP Coronary Ostial CannulaeK263596 | Medtronic, Inc. | 510(k) clearance | Oct 29, 2026 | FDA |
Dual Stage Venous CannulaeK263092 | Sorin Group Italia S.R.L. | 510(k) clearance | Oct 1, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Sorin Group Italia S.R.L.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Mirandola
Sources and methodology
- Original FDA record: K262052
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

